1.0
5 Mar 2021
Recommend
CEO approval
Business outlook
Pros
Business and the clinical team might be good and pampered well
Cons
Not valuing the scientists. All they care at this moment is to get the drug approved and research is a byproduct. Senior management doesn’t feel like there’s a clear direction. There’s a huge gap in terms of title between the seasoned employees and the new hires. They tend to sugarcoat stuff to attract new people. Lots of micromanaging going on even from the senior leaderships CSO was taking attendance by coming to the labs when they were open on last spring to check on people.